Insulet Corporation $PODD Position Boosted by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its shares in Insulet Corporation by 7.7% during Q2, holding a total of 14,085 shares valued at $4,425,000.
• Analysts have a consensus rating of "Moderate Buy" for Insulet, with a price target of $343.06, supported by positive reports from multiple firms including Citigroup and Wells Fargo.
• Insulet reported a 32.9% increase in revenue year-over-year, with an earnings per share (EPS) of $1.17 for the last quarter, surpassing analyst expectations.

IFM Investors Pty Ltd raised its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 7.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,085 shares of the medical instruments supplier's stock after purchasing an additional 1,003 shares during the quarter. IFM Investors Pty Ltd's holdings in Insulet were worth $4,425,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in Insulet in the 1st quarter worth approximately $26,000. SouthState Corp boosted its stake in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new stake in shares of Insulet during the second quarter worth $32,000. Finally, Ramirez Asset Management Inc. bought a new position in shares of Insulet during the 1st quarter worth approximately $53,000.

Insiders Place Their Bets

In related news, SVP Prem Singh sold 687 shares of the business's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company's stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on PODD. Barclays lifted their price target on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. The Goldman Sachs Group began coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Wells Fargo & Company boosted their target price on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Raymond James Financial restated an "outperform" rating and issued a $360.00 target price (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Finally, Truist Financial started coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $343.06.

Insulet Price Performance

NASDAQ PODD traded up $4.28 during trading on Monday, hitting $335.12. 431,486 shares of the stock traded hands, compared to its average volume of 593,672. The company has a market capitalization of $23.59 billion, a P/E ratio of 101.86, a price-to-earnings-growth ratio of 2.75 and a beta of 1.36. The firm has a 50-day simple moving average of $316.00 and a 200-day simple moving average of $295.09. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $225.37 and a 12-month high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's revenue was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.